| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemangioma, Cavernous, Central Nervous System | 40 | 2024 | 229 | 7.840 |
Why?
|
| Hemangioma, Cavernous | 8 | 2021 | 69 | 2.390 |
Why?
|
| Cerebral Hemorrhage | 11 | 2024 | 340 | 1.960 |
Why?
|
| Brain Neoplasms | 9 | 2023 | 782 | 1.570 |
Why?
|
| Biomarkers | 14 | 2024 | 1767 | 1.570 |
Why?
|
| Apoptosis Regulatory Proteins | 12 | 2023 | 198 | 1.040 |
Why?
|
| Disease Models, Animal | 11 | 2024 | 2366 | 0.830 |
Why?
|
| Capillary Permeability | 3 | 2021 | 130 | 0.820 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2024 | 12 | 0.800 |
Why?
|
| Intracranial Hemorrhages | 7 | 2024 | 130 | 0.760 |
Why?
|
| Hemorrhage | 8 | 2023 | 280 | 0.720 |
Why?
|
| Data Mining | 1 | 2020 | 43 | 0.710 |
Why?
|
| rho-Associated Kinases | 6 | 2019 | 160 | 0.710 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2020 | 82 | 0.700 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 51 | 0.690 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 308 | 0.640 |
Why?
|
| Nerve Tissue Proteins | 2 | 2024 | 511 | 0.630 |
Why?
|
| KRIT1 Protein | 9 | 2023 | 62 | 0.620 |
Why?
|
| Brain Injuries | 1 | 2020 | 164 | 0.610 |
Why?
|
| Brain | 9 | 2020 | 2285 | 0.600 |
Why?
|
| Iron | 3 | 2018 | 168 | 0.590 |
Why?
|
| X-Ray Microtomography | 2 | 2019 | 90 | 0.560 |
Why?
|
| Signal Transduction | 7 | 2024 | 3384 | 0.550 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2023 | 3448 | 0.540 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2024 | 424 | 0.540 |
Why?
|
| Transcriptome | 5 | 2024 | 630 | 0.540 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 168 | 0.500 |
Why?
|
| Seizures | 1 | 2017 | 306 | 0.490 |
Why?
|
| Circulating MicroRNA | 2 | 2024 | 13 | 0.450 |
Why?
|
| Vitamin D | 1 | 2016 | 269 | 0.450 |
Why?
|
| Cytokines | 1 | 2017 | 803 | 0.440 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2019 | 85 | 0.440 |
Why?
|
| Cohort Studies | 8 | 2024 | 2872 | 0.430 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2019 | 387 | 0.430 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2019 | 171 | 0.420 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1072 | 0.410 |
Why?
|
| Fibrinolytic Agents | 3 | 2019 | 217 | 0.410 |
Why?
|
| Algorithms | 1 | 2020 | 1877 | 0.400 |
Why?
|
| Humans | 50 | 2024 | 89356 | 0.400 |
Why?
|
| Male | 31 | 2024 | 42411 | 0.390 |
Why?
|
| Female | 31 | 2024 | 46202 | 0.370 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2022 | 253 | 0.370 |
Why?
|
| Mutation | 7 | 2024 | 4143 | 0.350 |
Why?
|
| Adult | 21 | 2024 | 26607 | 0.350 |
Why?
|
| Machine Learning | 3 | 2021 | 258 | 0.340 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 153 | 0.330 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2023 | 665 | 0.330 |
Why?
|
| Young Adult | 11 | 2024 | 6312 | 0.330 |
Why?
|
| Endothelial Cells | 9 | 2024 | 460 | 0.330 |
Why?
|
| Disease Progression | 5 | 2021 | 1489 | 0.330 |
Why?
|
| Mice | 17 | 2024 | 11761 | 0.320 |
Why?
|
| Zebrafish Proteins | 3 | 2024 | 149 | 0.300 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 232 | 0.290 |
Why?
|
| Middle Aged | 17 | 2024 | 25974 | 0.280 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 1574 | 0.280 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 605 | 0.280 |
Why?
|
| Zebrafish | 3 | 2024 | 319 | 0.270 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 3666 | 0.260 |
Why?
|
| Adolescent | 10 | 2020 | 9263 | 0.260 |
Why?
|
| Animals | 21 | 2024 | 27369 | 0.260 |
Why?
|
| Child, Preschool | 7 | 2020 | 3731 | 0.250 |
Why?
|
| Stroke | 3 | 2023 | 986 | 0.250 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2024 | 6 | 0.250 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2019 | 1242 | 0.250 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2024 | 64 | 0.240 |
Why?
|
| Propranolol | 2 | 2022 | 44 | 0.240 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2024 | 8 | 0.240 |
Why?
|
| Chemokine CX3CL1 | 1 | 2024 | 6 | 0.240 |
Why?
|
| Membrane Proteins | 3 | 2021 | 1223 | 0.240 |
Why?
|
| Prospective Studies | 7 | 2024 | 4289 | 0.230 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2020 | 36 | 0.230 |
Why?
|
| Astrocytes | 2 | 2021 | 141 | 0.230 |
Why?
|
| Kruppel-Like Transcription Factors | 5 | 2024 | 100 | 0.230 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2020 | 509 | 0.220 |
Why?
|
| Mice, Knockout | 7 | 2024 | 2001 | 0.220 |
Why?
|
| Radiation Injuries | 1 | 2024 | 162 | 0.210 |
Why?
|
| Aged | 13 | 2024 | 19165 | 0.210 |
Why?
|
| Neuronal Plasticity | 1 | 2024 | 194 | 0.200 |
Why?
|
| Contrast Media | 4 | 2023 | 1091 | 0.200 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2018 | 23 | 0.190 |
Why?
|
| Cerebral Veins | 1 | 2021 | 31 | 0.190 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2021 | 7 | 0.190 |
Why?
|
| Child | 7 | 2020 | 7174 | 0.190 |
Why?
|
| Acute Disease | 3 | 2020 | 841 | 0.190 |
Why?
|
| ADAMTS5 Protein | 1 | 2020 | 4 | 0.190 |
Why?
|
| Versicans | 1 | 2020 | 7 | 0.190 |
Why?
|
| Perfusion Imaging | 1 | 2021 | 50 | 0.190 |
Why?
|
| PubMed | 1 | 2020 | 13 | 0.180 |
Why?
|
| Time Factors | 4 | 2020 | 5338 | 0.180 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 588 | 0.180 |
Why?
|
| Glioma | 1 | 2023 | 294 | 0.180 |
Why?
|
| Brain Stem | 1 | 2021 | 167 | 0.180 |
Why?
|
| Hematoma | 2 | 2019 | 108 | 0.180 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2019 | 91 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 507 | 0.180 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 433 | 0.170 |
Why?
|
| Simvastatin | 2 | 2019 | 105 | 0.170 |
Why?
|
| Neurotoxins | 1 | 2020 | 49 | 0.170 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 48 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 114 | 0.170 |
Why?
|
| Plasma Cells | 1 | 2020 | 84 | 0.170 |
Why?
|
| Chronic Disease | 3 | 2020 | 950 | 0.170 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2020 | 50 | 0.170 |
Why?
|
| Autoantigens | 1 | 2020 | 129 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 3218 | 0.160 |
Why?
|
| Root Cause Analysis | 1 | 2018 | 3 | 0.160 |
Why?
|
| Protein C | 1 | 2018 | 5 | 0.160 |
Why?
|
| Thrombomodulin | 1 | 2018 | 7 | 0.160 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2018 | 10 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2020 | 268 | 0.160 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1862 | 0.160 |
Why?
|
| Zinc | 1 | 2019 | 93 | 0.160 |
Why?
|
| Cation Transport Proteins | 1 | 2019 | 67 | 0.160 |
Why?
|
| Cerebrovascular Circulation | 2 | 2021 | 230 | 0.150 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 82 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2020 | 166 | 0.150 |
Why?
|
| Thrombospondin 1 | 1 | 2017 | 21 | 0.150 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2019 | 113 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 191 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 1150 | 0.150 |
Why?
|
| Observer Variation | 2 | 2016 | 610 | 0.150 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2017 | 48 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2018 | 337 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2015 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2022 | 551 | 0.140 |
Why?
|
| Social Dominance | 1 | 2017 | 30 | 0.140 |
Why?
|
| Prognosis | 2 | 2024 | 3783 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2018 | 261 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 289 | 0.140 |
Why?
|
| Permeability | 3 | 2021 | 137 | 0.140 |
Why?
|
| Histological Techniques | 1 | 2016 | 36 | 0.140 |
Why?
|
| Orientation | 1 | 2017 | 119 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2017 | 371 | 0.140 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2758 | 0.140 |
Why?
|
| Iodine | 1 | 2016 | 43 | 0.140 |
Why?
|
| Hypertension | 1 | 2022 | 745 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 645 | 0.130 |
Why?
|
| Bayes Theorem | 3 | 2022 | 370 | 0.130 |
Why?
|
| ROC Curve | 1 | 2018 | 781 | 0.130 |
Why?
|
| Organ Size | 1 | 2016 | 371 | 0.130 |
Why?
|
| Demography | 1 | 2016 | 183 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2018 | 427 | 0.130 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 192 | 0.120 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 739 | 0.120 |
Why?
|
| Leukocytes | 1 | 2016 | 204 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2017 | 370 | 0.120 |
Why?
|
| Phenotype | 4 | 2024 | 2440 | 0.120 |
Why?
|
| Social Behavior | 1 | 2017 | 299 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2017 | 430 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2023 | 8241 | 0.110 |
Why?
|
| Apoptosis | 1 | 2019 | 1717 | 0.100 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 2 | 2021 | 13 | 0.090 |
Why?
|
| Recovery of Function | 2 | 2024 | 293 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 1431 | 0.090 |
Why?
|
| Perfusion | 2 | 2021 | 236 | 0.090 |
Why?
|
| Neurosurgery | 2 | 1982 | 100 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 377 | 0.080 |
Why?
|
| Lipopolysaccharides | 2 | 2020 | 293 | 0.070 |
Why?
|
| Risk Factors | 3 | 2024 | 5499 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 640 | 0.070 |
Why?
|
| Neoplasms | 2 | 2021 | 3041 | 0.070 |
Why?
|
| Neurosurgical Procedures | 2 | 2020 | 232 | 0.060 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 200 | 0.060 |
Why?
|
| Professional Practice | 3 | 1981 | 46 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 871 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2019 | 1719 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1719 | 0.060 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2024 | 50 | 0.060 |
Why?
|
| Cranial Irradiation | 1 | 2024 | 40 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 2340 | 0.060 |
Why?
|
| Genotype | 2 | 2021 | 1849 | 0.060 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2024 | 138 | 0.060 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2024 | 109 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 136 | 0.050 |
Why?
|
| Brain Mapping | 2 | 2017 | 564 | 0.050 |
Why?
|
| Aging | 2 | 2020 | 718 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2023 | 74 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2024 | 529 | 0.050 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2024 | 99 | 0.050 |
Why?
|
| Specialization | 1 | 1982 | 66 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2024 | 364 | 0.050 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 13 | 0.050 |
Why?
|
| Water | 1 | 2023 | 283 | 0.050 |
Why?
|
| Commission on Professional and Hospital Activities | 1 | 1981 | 1 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 29 | 0.050 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 69 | 0.050 |
Why?
|
| Medicine | 1 | 1982 | 91 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2021 | 89 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2021 | 99 | 0.050 |
Why?
|
| Medical Audit | 1 | 1981 | 39 | 0.050 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2021 | 22 | 0.050 |
Why?
|
| ADAMTS4 Protein | 1 | 2020 | 4 | 0.050 |
Why?
|
| ADAMTS1 Protein | 1 | 2020 | 6 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 46 | 0.050 |
Why?
|
| Patient Participation | 1 | 2023 | 224 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2021 | 38 | 0.050 |
Why?
|
| Craniotomy | 1 | 2021 | 88 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2020 | 149 | 0.050 |
Why?
|
| Cyclic N-Oxides | 1 | 2020 | 33 | 0.050 |
Why?
|
| Cholecalciferol | 1 | 2020 | 35 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 51 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 481 | 0.040 |
Why?
|
| Vimentin | 1 | 2020 | 46 | 0.040 |
Why?
|
| Spin Labels | 1 | 2020 | 106 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 856 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 155 | 0.040 |
Why?
|
| Tubulin | 1 | 2020 | 59 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2023 | 866 | 0.040 |
Why?
|
| Biopsy | 1 | 2024 | 1184 | 0.040 |
Why?
|
| Proteolysis | 1 | 2020 | 110 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 463 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 170 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 91 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 297 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 187 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2021 | 279 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2019 | 68 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2021 | 524 | 0.040 |
Why?
|
| White Matter | 1 | 2020 | 84 | 0.040 |
Why?
|
| Metagenomics | 1 | 2020 | 91 | 0.040 |
Why?
|
| Migraine Disorders | 1 | 2020 | 40 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 171 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2019 | 22 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 111 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2019 | 85 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 243 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 248 | 0.040 |
Why?
|
| Patient Selection | 1 | 2023 | 684 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2019 | 77 | 0.040 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 92 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2020 | 342 | 0.040 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2018 | 4 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 294 | 0.040 |
Why?
|
| Otolaryngology | 1 | 1979 | 55 | 0.040 |
Why?
|
| Hypoxia | 1 | 2024 | 653 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 202 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2019 | 183 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6811 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 312 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 330 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 444 | 0.040 |
Why?
|
| Occludin | 1 | 2018 | 66 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2018 | 92 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2019 | 133 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 198 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2019 | 353 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 175 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2021 | 411 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2019 | 344 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 682 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 329 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 1213 | 0.040 |
Why?
|
| Gram-Negative Bacteria | 1 | 2017 | 35 | 0.040 |
Why?
|
| Catheters | 1 | 2017 | 76 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2020 | 162 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2020 | 274 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2017 | 75 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2017 | 240 | 0.040 |
Why?
|
| Intestines | 1 | 2020 | 416 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 1982 | 645 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2019 | 230 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 448 | 0.040 |
Why?
|
| Colitis | 1 | 2019 | 244 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 212 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 780 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 414 | 0.030 |
Why?
|
| Cerebellum | 1 | 2018 | 249 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1132 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 376 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2019 | 681 | 0.030 |
Why?
|
| Pattern Recognition, Visual | 1 | 2017 | 155 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 134 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2019 | 689 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1668 | 0.030 |
Why?
|
| Age Factors | 2 | 2016 | 1870 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2017 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 805 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2017 | 501 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2303 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 1765 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 688 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2884 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1224 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1549 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 788 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2015 | 400 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 9057 | 0.020 |
Why?
|
| Primary Health Care | 3 | 1982 | 351 | 0.020 |
Why?
|
| United States | 4 | 1982 | 6989 | 0.020 |
Why?
|
| Task Performance and Analysis | 2 | 1981 | 87 | 0.010 |
Why?
|
| Practice Management, Medical | 2 | 1979 | 23 | 0.010 |
Why?
|
| Neurology | 1 | 1982 | 74 | 0.010 |
Why?
|
| Diagnostic Services | 1 | 1979 | 3 | 0.010 |
Why?
|
| Organizational Affiliation | 1 | 1979 | 6 | 0.010 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 1979 | 8 | 0.010 |
Why?
|
| Therapeutics | 1 | 1979 | 12 | 0.010 |
Why?
|
| Rural Health | 1 | 1979 | 21 | 0.010 |
Why?
|
| Urban Health | 1 | 1979 | 56 | 0.010 |
Why?
|
| Certification | 1 | 1979 | 61 | 0.010 |
Why?
|
| Patients | 1 | 1979 | 102 | 0.010 |
Why?
|
| Dermatology | 1 | 1978 | 40 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1979 | 341 | 0.010 |
Why?
|
| Sex Factors | 1 | 1979 | 1066 | 0.010 |
Why?
|
| Infant | 2 | 1979 | 3160 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1979 | 2485 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1978 | 187 | 0.000 |
Why?
|
| Skin Diseases | 1 | 1978 | 173 | 0.000 |
Why?
|